A 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC) presented to the hospital with pain in the perineal region. He had been taking lenvatinib every day for 2 months after he was diagnosed with HCC with metastases to the lymph node, small bowel mesentery, and retroperitoneal space. Enhanced abdominal computed tomography revealed mild elevation in intensity in the perineal subcutaneous tissue with subcutaneous emphysema. The patient was diagnosed with Common Terminology Criteria for Adverse Events grade 3, skin ulceration of stage IV with full-thickness skin loss and tissue necrosis in the muscular layer. The patient was taken off the medication with prescription of antibiotics, and after 3 weeks, the skin has fully recovered. This is the first report of an HCC patient who presented with a skin ulceration of stage IV after lenvatinib treatment. We recommend stopping the medication immediately and changing to alternative treatments with appropriate supportive care.
Citations
Citations to this article as recorded by
Multiple lenvatinib‐associated skin ulcers: A case report and literature review Soo Hyun Jeon, Woo Jin Lee, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Joon Min Jung Australasian Journal of Dermatology.2023;[Epub] CrossRef
Jae Hong Ahn, Hyung Joon Yim, Seung Young Kim, Jeong Han Kim, Yeon Seok Seo, Seung Hwa Lee, Hwan Hoon Chung, Tae Jin Song, Hong Sik Lee, Sang Woo Lee, Soon Ho Um, Jai Hyun Choi, Ho Sang Ryu
Journal of the Korean Liver Cancer Study Group. 2009;9(1):29-32. Published online June 30, 2009
Hepatic resection is a standard curative therapy for hepatocellular carcinoma (HCC) although only 10~30% of patients are
indicated due to advanced stage or poor hepatic reserve. Five year survival rate after resection was reported as a mean of
55% (25~93%), but cases of early recurrence after hepatic resection had poor prognosis. As early recurrence after hepatic
resection is the one of the most important factors that determines the prognosis, many investigators have been trying to
determine the factors associated with early recurrence. We report a case of early multiple recurrence of HCC after curative
hepatic resection probably due to microvascular invasion of tumor and too close resection margin. We would like to suggest
that additional prophylactic measures need to be sought in this group of patients because these factors may influence on early
recurrence.
Jeong Han Kim, Hyung Joon Yim, Seung Young Kim, Jae Hong Ahn, Ji Hoon Kim, Yeon Seok Seo, Seung Hwa Lee, Hwan Hoon Chung, Tae Jin Song, Hong Sik Lee, Sang Woo Lee, Jai Hyun Choi
Journal of the Korean Liver Cancer Study Group. 2009;9(1):63-66. Published online June 30, 2009
Surgical resection is the treatment of choice for hepatocellular carcinoma (HCC) in non-cirrhotic patients. The optimal
indication for resection is a single tumor in a suitable location for resection. However, limit of the tumor size is not clear.
We report a case of successful hepatic resection in patients with massive HCC sized more than 15 cm that did not respond
to transarterial chemoembolization (TACE). A 49-year-old male patient had received TACE two times for massive HCC.
However, the tumor size increased. Right hemihepatectomy was performed despite the extensive tumor size and underlying
liver cirrhosis. Ascites and wound infection were developed after resection, but the patient’s general condition got recovered
soon. Until 6 months after surgery, recurrence has not been detected. However, distant metastasis was noted at 7th month.
Although recurrence with distant metastasis was noted, we think aggressive surgical approach prolonged this patient’s
survival.
Seung Young Kim, Hyung Joon Yim, Jae Hong Ahn, Sung Woo Jung, Jeong Han Kim, Ji Hoon Kim, Ju-Han Lee, Seung Hwa Lee, Hwan Hoon Chung, jong Eun Yeon, Hong Sik Lee, Sang Woo Lee, Kwan Soo Byun, Jai Hyun Choi
Journal of the Korean Liver Cancer Study Group. 2009;9(1):86-89. Published online June 30, 2009
Helatocellular carcinoma (HCC) is uncommon in young adults, and young HCC patients is known to show poor prognosis
than older HCC patients because they have a more advanced tumor stage at diagnosis. We describe a case of HCC in a
28-year old chronic hepatitis B virus carrier who showed multiple nodular HCC with bone metastasis at diagnosis. In spite
of multidisciplinary treatment including transarterial chemoembolization (TACE) for liver mass and radiotherapy for metastatic
bone lesion, the patient died of cancer progression and weakened general condition 15 months after diagnosis. Therefore, we
need to consider periodic surveillance in young chronic hepatitis B virus carriers.